Diprometa (Betamethasone) [Diprospan] suspension for injection
23862USD

Diprometa (Betamethasone) [Diprospan] suspension for injection

SKU:2483
To favorites
Diprometa (Betamethasone) [Diprospan] has anti-inflammatory, anti-allergic and immunosuppressive effects
Active substance:Betamethasone
Pharmacological group:anti-inflammatory
Formulation:ampoules
Country of origin:Romania
In stock
$38
11
Description
Features
Reviews

Instructions for Diprometa (Betamethasone) [Diprospan] suspension for injection

Description Diprospan

the injection suspension contains white or almost white particles and is easily resussible. Does not contain any foreign content.
A slight shake produces a white or slightly yellowish suspension.

Active substances Diprospan

Betamethasone
Release Form
Suspension

Composition Betamethasone
1 ml contains:

active substances Diprospan:
betamethasone dipropionate - 6.43 mg in terms of betamethasone - 5.00 mg;
Sodium phosphate betamethasone - 2.63 mg per betamethasone - 2.00 mg;

Auxiliary substances Betamethasone:

methylparahydroxybenzoate - 1.30 mg;
propyl parhydroxybenzoate - 0.20 mg;
Benzyl alcohol - 9.00 mg;
macrogol-4000 - 20.00 mg;
sodium carmellose - 5.00 mg;
Dodecahydrate phosphate sodium - 5.04 mg;
- 0.10 mg of edetate;
sodium chloride - 5.00 mg;
polysorbate 80 - 0.625 mg; chlorohydric acid solution 1 M - up to pH = 7.4 ± 0.1;
water for injection - up to 1.00 ml (1.0127 g).

Pharmacological effect Diprospan

Glucocorticosteroid

Betamethasone is a synthetic GCS with a high glucocorticosteroid activity and a low mineralocorticoid activity. Betamethasone has anti-inflammatory, anti-allergic and immunosuppressive effects, as well as a pronounced and varied effect on various types of metabolism.

It interacts with specific cytoplasmic receptors to form a complex that penetrates into the nucleus of the cell and stimulates the synthesis of matrix ribonucleic acid, the latter inducing the formation of proteins, including lipocortin, mediating cellular effects. Lipocortin inhibits phospholipase A2, suppresses the release of arachidonic acid and suppresses the synthesis of endoprekices, prostaglandins, leukotrienes, which contribute to inflammation, allergies, etc.
Protein metabolism: reduces the amount of protein in blood plasma (due to globulins) with an increase in albumin/globulin ratio, increases albumin synthesis in the liver and kidneys, enhances protein catabolism in muscle tissue.

Pharmacokinetics Diprospan

Sodium betamethasone phosphate is well soluble in water and after intramuscular administration is quickly hydrolyzed and almost immediately absorbed from the site of administration, which provides a quick start of therapeutic action. Almost completely removed within one day after the introduction.

Betamethasone dipropionate is slowly absorbed from the depot, metabolized gradually, resulting in a long-term drug effect, and excreted for more than 10 days.
Betamethasone binds well to plasma proteins (62.5%).
It is metabolized in the liver to form mostly inactive metabolites. It is mainly removed by the kidneys.

Testimony Diprospan

Treatment in conditions and diseases in which GCS therapy allows to achieve the necessary clinical effect (it must be borne in mind that in some diseases GCS therapy is additional and does not replace the standard therapy):

Diseases of the musculoskeletal system and soft tissues, including rheumatoid arthritis, osteoarthrosis, bursitis, ankylosing spondyloarthritis, epicondylitis, coccigodinium, curvaceous, ganglion cyst, fasciitis.
Allergic diseases, including bronchial asthma, hay fever (pollinosis), allergic bronchitis, seasonal or year-round rhinitis, drug allergy, whey disease, reactions to insect bites.
Dermatological diseases, including atopic dermatitis, monoid eczema, neurodermites, contact dermatitis, pronounced photodermatitis, urticaria, red flat foliage, nodule alopecia, discoid red lupus, psoriasis, keloid scarring, common bubble chatter, cystic acne.
Systemic connective tissue diseases, including systemic lupus erythematosus, scleroderma, dermatomyositis, nodular periarteritis.
Haemoblastosis (palliative care of leukemia and lymphoma in adults, acute leukemia in children).
Primary or secondary adrenal cortex insufficiency (with mandatory simultaneous application of mineralocorticoids).
Other diseases and pathological conditions requiring systemic GCS therapy (adrenal syndrome, regional ileitis, blood pathological changes if GCS is needed).

Method of use and doses Diprospan

Intramuscular, intra-articular, near-articular, intrabursal, intra-dermal, intratural and intrauterine injections.
The small size of the crystals of betamethasone dipropionate allows the use of needles of a small diameter (26 caliber) for intradermal introduction and introduction directly into the lesion site.

DO NOT INJECT! DO NOT ENTER SUBCUTANEOUSLY!

Features
Active substance
Pharmacological group
Formulation
Country of origin
Expiration Date
No reviews yet — your comment may be first.
All reviews 0
general rating